CorMedix
CorMedix
CRMD
NASDAQ
6.24
USD
-29.65%
About
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter.
DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 776.4K |
| Three Month Average Volume | 12.2M |
| High Low | |
| Fifty-Two Week High | 7 USD |
| Fifty-Two Week Low | 2.57 USD |
| Fifty-Two Week High Date | 12 Apr 2024 |
| Fifty-Two Week Low Date | 15 Nov 2023 |
| Price and Volume | |
| Current Price | 6.24 USD |
| Beta | 2 |
| Relative Price Change | |
| Four Week Relative Price Change | 39.97% |
| Thirteen Week Relative Price Change | 10.63% |
| Twenty-Six Week Relative Price Change | 54.64% |
| Fifty-Two Week Relative Price Change | 22.35% |
| Year-to-Date Relative Price Change | 40.14% |
| Price Change | |
| One Day Price Change | 2.80% |
| Thirteen Week Price Change | 18.41% |
| Twenty-Six Week Price Change | 70.03% |
| Five Day Price Change | 10.44% |
| Fifty-Two Week Price Change | 53.32% |
| Year-to-Date Price Change | 65.96% |
| Month-to-Date Price Change | 36.24% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.27675 USD |
| Book Value Per Share (Most Recent Quarter) | 0.83553 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.27675 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.80029 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.01257 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.01407 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -0.91034 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -0.92622 USD |
| Normalized (Last Fiscal Year) | -0.91034 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -0.91034 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -0.92622 USD |
| Including Extraordinary Items (Last Fiscal Year) | -0.91034 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -0.92622 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.38393 USD |
| Cash Per Share (Most Recent Quarter) | 0.82516 USD |
| Cash Flow Per Share (Last Fiscal Year) | -0.90895 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -0.92485 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -0.89369 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -15,801 |
| Cash Flow Revenue (Trailing Twelve Months) | -6,351 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -6,762.12% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -19,872.62% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -64.79% |
| Gross Margin (5 Year) | 6.18% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -7,212.46% |
| Operating Margin (5 Year) | -20,189.76% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -6,589.09% |
| Net Profit Margin (5 Year) | -18,323.42% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | 41.31% |
| Tangible Book Value (5 Year) | 70.04% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 2,107.34% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 46.27% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 1.17% |
| EPS Change (Trailing Twelve Months) | -8.88% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | 8 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -45,610,290 |
| Net Debt (Last Fiscal Year) | -76,030,810 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | 432 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 5 |
| Price to Book (Most Recent Quarter) | 7 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 7 |
| Quick Ratio (Most Recent Quarter) | 4 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 7 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -38,736,780 |
| Free Cash Flow (Trailing Twelve Months) | -51,195,650 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -64.32% |
| Return on Assets (Trailing Twelve Months) | -92.57% |
| Return on Assets (5 Year) | -54.84% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -74.02% |
| Return on Equity (Trailing Twelve Months) | -111.55% |
| Return on Equity (5 Year) | -76.06% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -73.33% |
| Return on Investment (Trailing Twelve Months) | -110.35% |
| Return on Investment (5 Year) | -62.32% |